Mutant Beta-Lactamases for GI Antibiotic Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic treatments for gastrointestinal tract disorders, such as C. difficile infection, disrupt the microbiome and lead to undesirable effects like antibiotic-associated diarrhea and pathogenic bacteria overgrowth, necessitating a solution to rebalance the intestinal microbiota.
Innovation Solution
Development of mutant beta-lactamases with enhanced substrate specificity and activity, capable of hydrolyzing penicillins and cephalosporins, to inactivate excess antibiotics in the gastrointestinal tract, thereby preventing microbiome disruption and associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-lactam antibiotics are administered to treat infections, then therapeutic effect is achieved, but microbiome disruption and antibiotic-associated diarrhea occur
Solution Approach 1:
The patent extracts and removes excess beta-lactam antibiotics from the gastrointestinal tract using beta-lactamase enzymes. The enzymes specifically target and hydrolyze unabsorbed antibiotics in the gut, separating the therapeutic effect (systemic antibiotic action) from the harmful residue (intestinal disruption), thereby resolving the contradiction between treatment efficacy and microbiome preservation
Solution Approach 2:
Beta-lactamase enzymes serve as an intermediary substance that mediates between the administered antibiotics and the microbiome. The enzymes are administered systemically or locally, travel to the gastrointestinal tract, and selectively neutralize excess antibiotics without directly interacting with or harming the microbiome, thus protecting the ecological balance while maintaining therapeutic benefits
2Stability of the object's composition
If beta-lactamase is used to inactivate excess antibiotics in the GI tract, then microbiome balance is preserved, but systemic antibiotic utility may be reduced
Solution Approach 1:
The patent applies local quality by creating spatial differentiation in beta-lactamase activity. The enzymes are concentrated in the gastrointestinal tract where they selectively inactivate excess antibiotics, while systemic circulation maintains sufficient antibiotic levels for therapeutic effect. This localized action preserves microbiome balance without compromising overall treatment efficacy
Solution Approach 2:
The patent employs partial action by using beta-lactamase to inactivate only the excess, unabsorbed antibiotics in the gastrointestinal tract rather than all antibiotics in the body. This selective partial neutralization preserves the therapeutic concentration needed for infection treatment while removing the harmful surplus that disrupts the microbiome
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant beta-lactamases effectively clear excess antibiotics from the GI tract, preventing disruption of the microbiota and allowing for safe antibiotic therapy without interfering with systemic antibiotic utility, thus addressing C. difficile infection and other antibiotic-induced adverse effects.
Implementation Method 1
the therapeutic use of beta-lactamases, for example, by inactivating excreted or unabsorbed antibiotics in the GI tract
Data Source
AI summary
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).